Enhancement of cyclosporin A-induced autologous graft-versus-host disease after peripheral blood stem cell transplantation by utilizing selected CD34+ cells

Bone Marrow Transplantation

Volumn 32, Issue 8, 2003, Pages 785-790

  Miura, Y ^a,b   Ueda, M ^c   Takami, A ^b   Shiobara, S ^b   Nakao, S ^b   Hess, A D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^c ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Autologous graft versus host disease; CD34 selected peripheral blood stem cell transplantation; Cyclosporin A

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; RANIMUSTINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER REGRESSION; CELL TRANSFER; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENTEROPATHY; ERYTHEMA; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER DISEASE; MALE; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RASH; SKIN BIOPSY; T LYMPHOCYTE;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CELL SEPARATION; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; MALE; MIDDLE AGED;

EID: 1342323791     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704208     Document Type: Article

References (37)

1. Glazier A, Tutschika PJ, Farmer ER, Santos GW. Graft-versus-host disease in cyclosporine treated rats after syngeneic autologous bone marrow reconstitution. J Exp Med 1983; 158: 1-8.
2. Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft-vs-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 1985; 161: 718-730.
3. Jones RJ, Vogelsang GB, Hess AD et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 333: 754-756.
4. Fischer AC, Beschorner WE, Hess AD. Requirements for the induction and adoptive transfer of cyclosporine-induced syngeneic graft-versus-host disease. J Exp Med 1989; 169: 1031-1041.
5. Vogelsang GB, Hess AD. Graft-versus-host disease: New directions for a persistent problem. Blood 1994; 84: 2061-2067.
6. Miura Y, Thoburn CJ, Bright EC et al. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): Interleukin-10 and interferon-gamma may be critical mediators for the development of autologous GVHD. Blood 2002; 100: 2650-2658.
7. Geller RB, Esa AH, Beschorner WE et al. Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 1989; 74: 1165-1171.
8. Hess AD, Bright EC, Thoburn CJ et al. Specificity of effector T lymphocytes in autologous graft-versus-host disease: Role of the major histocompatibility complex class II invariant chain peptide. Blood 1997; 89: 2203-2209.
9. Hess AD, Thoburn CJ. Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease. Immunol Rev 1997; 157: 111-123.
10. Dolei A, Capobianchi MR, Ameglio F. Human interferon-gamma enhances the expression of class I and class II major histocompatibility complex products in neoplastic cells more effectively than interferon-alpha and interferon-beta. Infect Immunol 1983; 40: 172-176.
11. Noga SJ, Horwitz L, Kim H et al. Interferon-gamma potentiates the antitumor effect of cyclosporine-induced autoimmunity. J Hematother 1992; 1: 75-84.
12. Yeager AM, Vogelsang GB, Jones RJ et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031-3035.
13. Vogelsang G, Bitton R, Piantadosi S et al. Immune modulation in autologous bone marrow transplantation: Cyclosporine and gamma-interferon trial. Bone Marrow Transplant 1999; 24: 637-640.
14. Marin GH, Porto A, Prates V et al. Graft versus host disease in autologous stem cell transplantation. J Exp Clin Cancer Res 1999; 18: 201-208.
15. Miura Y, Ueda M, Zeng W et al. Induction of autologous graft-versus-host disease with cyclosporine A after peripheral blood stem cell transplantation: Analysis of factors affecting induction. J Allergy Clin Immunol 2000; 106: 51-57.
16. van der Wall E, Horn T, Bright E et al. Autologous graft-versus-host disease induction in advanced breast cancer: Role of peripheral blood progenitor cells. Br J Cancer 2000; 83: 1405-1411.
17. Pati AR, Godder KT, Abhyankar SH et al. Cyclosporine-induced autologous graft-versus-host disease following autologous blood stem cell transplantation for lymphoma. Bone Marrow Transplant 1996; 17: 1081-1083.
18. Hess AD, Fischer AC, Horwitz L et al. Characterization of peripheral autoregulatory mechanisms that prevent development cyclosporine-induced syngeneic graft-versus-host disease. J Immunol 1994; 153: 400-411.
19. Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987; 49: 273-280.
20. Aguilar LK, Aguilar-Cordova E, Cartwright Jr J, Belmont JW. Thymic nurse cells are sites of thymocyte apoptosis. J Immunol 1994; 152: 2645-2651.
21. Jenkins MK, Schwartz RH, Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science 1988; 241: 1655-1658.
22. Gao EK, Lo D, Cheney R et al. Abnormal differentiation of thymocytes in mice treated with cyclosporin A. Nature 1988; 336: 176-179.
23. Hess AD, Fischer AC, Horwitz L et al. Characterization of peripheral autoregulatory mechanisms that prevent development cyclosporine-induced syngeneic graft-versus-host disease. J Immunol 1994; 53: 400-411.
24. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-1722.
25. + bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 1995; 85: 1647-1654.
26. Foucar K, McKenna RW, Frizzera G et al. Incidence and patterns of bone marrow and blood involvement by lymphoma in relationship to the Lukes-Collins classification. Blood 1979; 54: 1417-1422.
27. + peripheral-blood stem-cell transplants for follicular lymphoma: A pilot study. J Clin Oncol 1997; 15: 2288-2295.
28. Takahashi T, Kanda Y, Mori M et al. B cell lymphoma-associated hemophagocytic syndrome after PBSCT. Bone Marrow Transplant 1998; 21: 623-625.
29. Fischer AC, Hess AD. Age-related factors in cyclosporine-induced syngeneic graft-versus-host disease: Regulatory role of marrow-derived T lymphocytes. J Exp Med 1990; 172: 85-94.
30. Fischer AC, Laulis MK, Horwitz L et al. Host resistance to cyclosporine induced syngeneic graft-versus-host disease. Requirement for two distinct lymphocyte subsets. J Immunol 1989; 143: 827-832.
31. Wu DY, Goldschneider I. Cyclosporin A-induced autologous graft-versus-host disease: A prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants. J Immunol 1999; 162: 6926-6933.
32. Mielcarek M, Graf L, Johnson G, Torok-Storb B. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: A mechanism for monocyte-mediated suppression of T-cell proliferation. Blood 1998; 92: 215-222.
33. +) in the blood of normal donors. Blood 1997; 89: 2586-2595.
34. Sica S, Chiusolo P, Salutari P et al. Autologous graft-versus-host disease after CD34+-purified autologous peripheral blood progenitor cell transplantation. J Hematother Stem Cell Res 2000; 9: 375-379.
35. Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral-blood progenitor-cell transplantation in 60 patients with poor prognosis follicular lymphoma. Blood 1995; 86: 3257-3262.
36. Schultze JL, Seamon MJ, Michalak S et al. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997; 89: 3806-3816.
37. Dorfman DM, Schultze JL, Shahsafaei A et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997; 90: 4297-4306.